WuL, GerardNP, WyattR, et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature, 1996; 6605:179–183.
2.
DemarestJ, BonnyT, VavroC, et al. HIV-1 co-receptor tropism in treatment naive and experienced subjects. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 30–November 2, 2004, Washington, D.C. Abstract H-1136.
3.
WilkinTJ, SuZ, KuritzkesDR, et al. HIV type 1 chemokine co-receptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis, 2007; 44:591–595. [Erratum: Clin Infect Dis 2007;44:1399.]
4.
GulickRM, LalezariJ, GoodrichJ, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med, 2008; 359:1429.
5.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January10, 2011. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL002111.pdf (Last accessed February2, 2014).
6.
KootM, KeetIP, VosAH, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med, 1993; 118:681–688.
